Huntington’s Disease (HD)


Biomarkers and precision medicine are inextricably linked these days in what are known as molecularly targeted therapies. Low abundance circulating proteins have the potential to be used as disease prevention and diagnostic tool as well as biomarkers to quantify therapeutic efficacy.

Using Singulex Erenna® Immunoassay Platform we found correlation of mutant Huntingtin level in patient’s cerebrospinal fluid with Huntington’s disease stages.